ifosfamide has been researched along with Bladder Cancer in 44 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Phase II trial in metastatic urothelial carcinoma using a novel combination chemotherapy regimen consisting of vinblastine, ifosfamide, and gallium nitrate (VIG)." | 9.07 | Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. ( Ansari, R; Dreicer, R; Einhorn, LH; Gonin, R; Loehrer, PJ; Roth, BJ, 1994) |
| " Mesna was administered intravenously at a 20% of the ifosfamide dosage before ifosfamide and orally at 40% after 4 and 8 hours from the ifosfamide infusion." | 6.68 | Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997) |
| "Although chemotherapy for advanced bladder cancer has historically been based on cisplatin-based combination regimens, the limitations of these regimens both in terms of efficacy and toxicity are now widely appreciated." | 6.39 | Ifosfamide in the treatment of bladder cancer. ( Roth, BJ, 1996) |
| "Phase II trial in metastatic urothelial carcinoma using a novel combination chemotherapy regimen consisting of vinblastine, ifosfamide, and gallium nitrate (VIG)." | 5.07 | Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. ( Ansari, R; Dreicer, R; Einhorn, LH; Gonin, R; Loehrer, PJ; Roth, BJ, 1994) |
| " In untreated patients, paclitaxel has demonstrated significant activity and is certainly among the most active single agents in the treatment of advanced bladder cancer." | 4.79 | Palliative chemotherapy in advanced bladder cancer. ( Roth, BJ, 1995) |
| "The activity of ifosfamide in genitourinary malignancies has been documented in testicular cancer and bladder cancer." | 4.79 | The role of ifosfamide in the treatment of testicular and urothelial malignancies. ( Roth, BJ, 1996) |
| "To evaluate the efficacy and toxicity of perioperative combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP) in bladder cancer patients with regional lymph node metastases treated by radical cystectomy." | 3.74 | Combination chemotherapy of ifosfamide, 5-fluorouracil, etoposide and cisplatin as perioperative treatment in lymph node positive bladder carcinoma patients treated by radical cystectomy. ( Fujii, Y; Fukui, I; Kawakami, S; Komai, Y; Okubo, Y; Yamamoto, S; Yonese, J, 2008) |
| "High-dose ifosfamide (HD-IFX) has shown significant antitumor activity in advanced sarcoma and breast carcinoma." | 3.69 | Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. ( Albanell, J; Baselga, J; Bellmunt, J; Casado, S; Eres, N; Ribas, A, 1997) |
| "There was only one postsurgical death." | 2.74 | Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. ( Dinney, CP; Grossman, HB; Kamat, AM; Millikan, RE; Qiao, W; Siefker-Radtke, AO; Thall, PF; Williams, DL, 2009) |
| "Gemcitabine was given on Day 2 and Day 4 at doses of 90 mg/m(2), 150 mg/m(2), and 200 mg/m(2) per dose." | 2.70 | Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin. ( Logothetis, CJ; Millikan, RE; Plunkett, WK; Smith, TL; Williams, DL, 2001) |
| "Advanced bilharzial bladder cancer is relatively sensitive to combination chemotherapy, but complete remission and prolonged survival is rare in this subgroup of patients with advanced disease." | 2.68 | Combination chemotherapy for advanced bilharzial bladder carcinoma. ( Abu Rabia, A; el-Attar, I; el-Said, A; Gaafar, R; Gad el-Mawla, N; Hamza, MR; Khaled, HM; Magrath, I, 1996) |
| " Mesna was administered intravenously at a 20% of the ifosfamide dosage before ifosfamide and orally at 40% after 4 and 8 hours from the ifosfamide infusion." | 2.68 | Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997) |
| "Prostate cancer, bladder cancer, renal cancer and testicular cancer are common among urological cancers." | 2.41 | [Chemotherapy and radiotherapy for urological cancer]. ( Akaza, H; Hattori, K; Kawai, K; Miyanaga, N; Shimazui, T; Tsukamoto, S; Uchida, K, 2002) |
| "Although chemotherapy for advanced bladder cancer has historically been based on cisplatin-based combination regimens, the limitations of these regimens both in terms of efficacy and toxicity are now widely appreciated." | 2.39 | Ifosfamide in the treatment of bladder cancer. ( Roth, BJ, 1996) |
| " A good performance status, lymph node metastasis alone and administration of chemotherapy at the full dosage had a significantly favorable impact on patient survival." | 1.31 | Combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin for metastatic urothelial cancer. ( Fukui, I; Ishiwata, D; Kim, T; Tohma, T; Tsukamoto, T; Yonese, J; Yoshida, T, 2001) |
| "They were 26 bladder cancers and 19 renal cell cancers." | 1.30 | Clinical application of an in vitro chemosensitivity test, the Histoculture Drug Response Assay, to urological cancers: wide distribution of inhibition rates in bladder cancer and renal cell cancer. ( Fujita, K; Hirano, Y; Suzuki, K; Ushiyama, T, 1999) |
| "We describe 2 cases of proximal tubular defects induced by the administration of ifosfamide at a dosage of 6 g/m2/course over 2 days in children with a diagnosis of malignant mesenchymal tumors." | 1.29 | Ifosfamide-induced renal tubular defect. ( López Pérez, J; Melero, C; Muley, R; Torres Valdivieso, MJ; Vara, J; Vivanco, JL, 1994) |
| "The patients with prostatic cancer were treated with VIP (vincristine, ifosfamide, peplomycin) chemotherapy and the patients with urothelial cancer were treated with MP (methotrexate, cisplatinum) or MEP (methotrexate, Etoposide, cisplatinum) combination chemotherapy." | 1.29 | [Comparative study on urinary parameters reflecting renal damage during chemotherapy for urological cancer]. ( Kitamura, Y; Komatsubara, S; Sakata, Y; Watanabe, M, 1993) |
| " (1) The tumor growth was inhibited by CDGP-II in all three different dosage groups (p < 0." | 1.29 | [Evaluation of the chemotherapy of a transplantable bladder tumour strain (NM-B-1) by two anti-cancer drugs in combination with a pressor agent in nude mice]. ( Akima, S; Horiuchi, K; Tsuboi, N; Yoshida, K, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (9.09) | 18.7374 |
| 1990's | 21 (47.73) | 18.2507 |
| 2000's | 15 (34.09) | 29.6817 |
| 2010's | 2 (4.55) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Hosomi, T | 1 |
| Shibasaki, N | 1 |
| Otsuka, H | 1 |
| Uketa, S | 1 |
| Makino, Y | 1 |
| Shichiri, Y | 1 |
| Howe, AS | 1 |
| Pearce, J | 1 |
| Lian, F | 1 |
| Ribbons, L | 1 |
| Chumbalkar, V | 1 |
| Nazeer, T | 1 |
| Kogan, BA | 1 |
| Komai, Y | 1 |
| Fujii, Y | 1 |
| Okubo, Y | 1 |
| Yamamoto, S | 1 |
| Kawakami, S | 2 |
| Yonese, J | 4 |
| Fukui, I | 4 |
| Siefker-Radtke, AO | 2 |
| Kamat, AM | 2 |
| Grossman, HB | 2 |
| Williams, DL | 3 |
| Qiao, W | 1 |
| Thall, PF | 1 |
| Dinney, CP | 2 |
| Millikan, RE | 3 |
| Milowsky, MI | 1 |
| Nanus, DM | 1 |
| Maluf, FC | 1 |
| Mironov, S | 1 |
| Shi, W | 1 |
| Iasonos, A | 1 |
| Riches, J | 1 |
| Regazzi, A | 1 |
| Bajorin, DF | 2 |
| Kitamura, H | 1 |
| Taguchi, K | 1 |
| Kunishima, Y | 1 |
| Yanase, M | 1 |
| Takahashi, A | 1 |
| Shigyo, M | 1 |
| Tanaka, T | 1 |
| Mutoh, M | 1 |
| Fukuta, F | 1 |
| Masumori, N | 1 |
| Tsukamoto, T | 3 |
| Shen, Y | 1 |
| Gonzalez-Angulo, AM | 1 |
| Orzano, JA | 1 |
| Davila, E | 1 |
| Maezawa, T | 1 |
| Ishii, N | 1 |
| Dalpiaz, O | 1 |
| al Rabi, N | 1 |
| Galfano, A | 1 |
| Martignoni, G | 1 |
| Ficarra, V | 1 |
| Artibani, W | 1 |
| Bex, A | 1 |
| Nieuwenhuijzen, JA | 1 |
| Kerst, M | 1 |
| Pos, F | 1 |
| van Boven, H | 1 |
| Meinhardt, W | 1 |
| Horenblas, S | 1 |
| Yokoyama, M | 1 |
| Kobayashi, T | 1 |
| Kubo, Y | 1 |
| Kageyama, Y | 1 |
| Kihara, K | 2 |
| Antonelli, A | 1 |
| Simeone, C | 1 |
| Ferrari, V | 1 |
| Tardanico, R | 1 |
| Cunico, SC | 1 |
| Lin, CC | 1 |
| Hsu, CH | 1 |
| Huang, CY | 1 |
| Keng, HY | 1 |
| Tsai, YC | 1 |
| Huang, KH | 1 |
| Cheng, AL | 1 |
| Pu, YS | 1 |
| Shaw, IC | 1 |
| Rose, JW | 1 |
| Minowa, T | 1 |
| Nakagami, Y | 1 |
| Hiraoka, Y | 1 |
| Nakajima, H | 1 |
| Lin, TD | 1 |
| Gad-el-Mawla, N | 1 |
| Ziegler, JL | 1 |
| Hamza, R | 1 |
| Elserafi, M | 1 |
| Khaled, H | 1 |
| Torres Valdivieso, MJ | 1 |
| López Pérez, J | 1 |
| Melero, C | 1 |
| Vivanco, JL | 1 |
| Muley, R | 1 |
| Vara, J | 1 |
| Einhorn, LH | 2 |
| Roth, BJ | 6 |
| Ansari, R | 1 |
| Dreicer, R | 2 |
| Gonin, R | 1 |
| Loehrer, PJ | 2 |
| Kitamura, Y | 1 |
| Watanabe, M | 1 |
| Komatsubara, S | 1 |
| Sakata, Y | 1 |
| Akima, S | 1 |
| Yoshida, K | 1 |
| Tsuboi, N | 1 |
| Horiuchi, K | 1 |
| Cassidy, J | 1 |
| Kaye, SB | 1 |
| Mahjoubi, M | 1 |
| Kattan, J | 1 |
| Droz, JP | 1 |
| Philippot, I | 1 |
| Pautier, P | 1 |
| Boutan-Laroze, A | 1 |
| Azab, M | 1 |
| Theodore, C | 1 |
| Khaled, HM | 1 |
| Gad el-Mawla, N | 1 |
| el-Said, A | 1 |
| Hamza, MR | 1 |
| Gaafar, R | 1 |
| el-Attar, I | 1 |
| Abu Rabia, A | 1 |
| Magrath, I | 1 |
| Propert, KJ | 1 |
| Bellmunt, J | 1 |
| Eres, N | 1 |
| Ribas, A | 1 |
| Casado, S | 1 |
| Albanell, J | 1 |
| Baselga, J | 1 |
| Kyriakakis, Z | 1 |
| Dimopoulos, MA | 1 |
| Kostakopoulos, A | 1 |
| Karayiannis, A | 1 |
| Sofras, F | 1 |
| Zervas, A | 1 |
| Giannopoulos, A | 1 |
| Dimopoulos, C | 1 |
| Pronzato, P | 1 |
| Vigani, A | 1 |
| Pensa, F | 1 |
| Vanoli, M | 1 |
| Tani, F | 1 |
| Vaira, F | 1 |
| Morrison, SC | 1 |
| O'Donnell, JK | 1 |
| Okada, Y | 1 |
| Fukuda, H | 1 |
| Nagahama, K | 1 |
| Saito, K | 1 |
| Ohtsuka, Y | 1 |
| Morita, T | 1 |
| Oshima, H | 1 |
| Eishi, Y | 1 |
| Kanno, J | 1 |
| Müller, M | 1 |
| Heicappell, R | 1 |
| Steiner, U | 1 |
| Goessl, C | 1 |
| Miller, K | 1 |
| Fagbemi, SO | 1 |
| Stadler, WM | 1 |
| Kitsukawa, S | 1 |
| Kinn, T | 1 |
| Yoshida, T | 2 |
| Izutami, T | 1 |
| Ishikawa, Y | 1 |
| Hirano, Y | 1 |
| Ushiyama, T | 1 |
| Suzuki, K | 1 |
| Fujita, K | 1 |
| Edelman, MJ | 1 |
| Plunkett, WK | 1 |
| Smith, TL | 1 |
| Logothetis, CJ | 1 |
| Kim, T | 1 |
| Tohma, T | 1 |
| Ishiwata, D | 1 |
| von der Maase, H | 1 |
| Miyanaga, N | 1 |
| Tsukamoto, S | 1 |
| Hattori, K | 1 |
| Kawai, K | 1 |
| Shimazui, T | 1 |
| Uchida, K | 1 |
| Akaza, H | 1 |
| Brock, N | 1 |
| Pohl, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Trial of Sequential Doxorubicin/Gemcitabine (AG) and Ifosfamide, Paclitaxel, and Cisplatin (ITP) Chemotherapy (AG-ITP) in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium[NCT00003105] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 1997-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for ifosfamide and Bladder Cancer
| Article | Year |
|---|---|
Small cell carcinoma of the bladder: a case report and a literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Small Cell; | 2003 |
Palliative chemotherapy in advanced bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; | 1995 |
Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1995 |
Ifosfamide in the treatment of bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 1996 |
The role of ifosfamide in the treatment of testicular and urothelial malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Clinical Trials as Top | 1996 |
[Small cell carcinoma of the urinary bladder: a case report and review of the Japanese literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality | 1997 |
New chemotherapy regimens for advanced bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopl | 1998 |
[Successful multidisciplinary treatment for bladder cancer with priapism. A case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Comb | 1998 |
New approaches to treatment of metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2000 |
Current and future perspectives in advanced bladder cancer: is there a new standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogeni | 2002 |
[Chemotherapy and radiotherapy for urological cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorubicin; Drug Administrati | 2002 |
12 trials available for ifosfamide and Bladder Cancer
| Article | Year |
|---|---|
Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 2009 |
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 2009 |
Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease-F | 2011 |
A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2013 |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2007 |
Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cal | 1994 |
Feasibility trial of a combination of vinorelbine, ifosfamide, fluorouracil and folinic acid (VIF regimen) in advanced urothelial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Feasibility Studies; Female; Fluorouracil; Hum | 1993 |
Combination chemotherapy for advanced bilharzial bladder carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 1996 |
Vinblastine, ifosfamide, and gallium nitrate--an active new regimen in patients with advanced carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E5892).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional | 1997 |
Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic A | 1997 |
Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer.
Topics: Administration, Oral; Aged; Alopecia; Ambulatory Care; Antineoplastic Agents, Alkylating; Bone Marro | 1997 |
Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin.
Topics: Adult; Aged; Alkylating Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2001 |
21 other studies available for ifosfamide and Bladder Cancer
| Article | Year |
|---|---|
[Advanced Bladder Cancer with Multiple Pulmonary Metastases Treated with Paclitaxel/Ifosfamide/Nedaplatin Therapy : Two Case Reports].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxy | 2023 |
A Case of Ewing Sarcoma of the Bladder Presenting in Early Infancy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Etopo | 2021 |
Combination chemotherapy of ifosfamide, 5-fluorouracil, etoposide and cisplatin as perioperative treatment in lymph node positive bladder carcinoma patients treated by radical cystectomy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2008 |
Ifosfamide-induced encephalopathy.
Topics: Antineoplastic Agents, Alkylating; Carcinoma, Transitional Cell; Encephalitis; Humans; Ifosfamide; M | 2002 |
[Combination chemotherapy with ifosfamide, 5-fuluorouracil, etoposide and cisplatin for advanced urothelial cancer: the treatment results and significance of tumor marker evaluation in response assessment of chemotherapy].
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 | 2002 |
Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer.
Topics: Age Factors; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell | 2005 |
[A case of secondary malignant lymphoma of the urinary bladder].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2006 |
Durable and complete remission of a metastatic bladder sarcomatoid carcinoma with chemotherapic and surgical treatments.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinoma, Transitional Cell; | 2006 |
Infusion of ifosphamide plus mesna.
Topics: Cyclophosphamide; Drug Interactions; Humans; Ifosfamide; Infusions, Parenteral; Mercaptoethanol; Mes | 1984 |
Trials of PIA (Cisplatin, Ifosfamide Adriamycin) therapy on bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Evaluation; Femal | 1984 |
Phase II chemotherapy trials of 5-FU, cyclophosphamide, ifosfamide, and vincristine in carcinoma of the bilharzial bladder.
Topics: Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Fluoroura | 1984 |
Ifosfamide-induced renal tubular defect.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Doxorubicin; Humans; | 1994 |
[Comparative study on urinary parameters reflecting renal damage during chemotherapy for urological cancer].
Topics: Acetylglucosaminidase; Adolescent; Adult; Aged; Aminopeptidases; Antineoplastic Combined Chemotherap | 1993 |
[Evaluation of the chemotherapy of a transplantable bladder tumour strain (NM-B-1) by two anti-cancer drugs in combination with a pressor agent in nude mice].
Topics: Angiotensin II; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cel | 1995 |
An unusual case of haematuria.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide | 1993 |
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Breast Neoplasms; Carcinoma, Transitional Cell; D | 1997 |
Ifosfamide-induced alteration of technetium-99m-DMSA renal parenchymal imaging.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; I | 1997 |
Side effects of chemotherapy for advanced urothelial carcinoma with etoposide and ifosfamide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Etoposide; Femal | 1997 |
Clinical application of an in vitro chemosensitivity test, the Histoculture Drug Response Assay, to urological cancers: wide distribution of inhibition rates in bladder cancer and renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Drug Resistance; Drug Sc | 1999 |
Combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin for metastatic urothelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Etoposide; Fema | 2001 |
Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
Topics: Animals; Biotransformation; Cyclophosphamide; DNA; Glutathione; Ifosfamide; Kidney; Leukemia, Experi | 1986 |